Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Interleukin-17A (IL-17) is a pro-inflammator¬y cytokine, which has been reported to be increased in the joint of patients with OA. This study aimed to identify whether IL-17 or its receptors are expressed in the joints of OA patients and establish the effect of IL-17 in vitro on primary human chondrocytes and synovial fibroblasts from the joints of OA patients. We further studied whether any anti-inflammatory agents in current clinical use were able to reduce the effects of IL-17. We hypothesize that IL-17 stimulates the production of matrix degrading and inflammatory proteins by acting on IL-17 receptors on chondrocytes and synovial fibroblasts, which can be blocked by clinically used anti-inflammatory therapeutics.

More information Original publication

DOI

10.1016/j.joca.2018.02.258

Type

Conference paper

Publisher

Elsevier

Publication Date

2018-04-16T00:00:00+00:00

Volume

26